Company: SNY
Filing Date: 2025-10-29
Form Type: 424B5
Source: 0001193125-25-255563
Chunk: 17

Company: Sanofi
Filing Date: 2025-10-29
Form: 424B5
Chunk 17
---
 depositing funds or obligations issued by the United States government 
 in an amount sufficient to provide for the timely payment of principal, interest and other amounts due under the notes as described under “Description of Debt Securities We May Offer—Special Situations—Defeasance and                            
 Discharge” in the attached prospectus.                                                                                                                                                                                                              |

| Sinking Fund | None. |

| Risk Factors | You should carefully consider all of the information in this prospectus supplement and the attached prospectus, which includes information incorporated by reference. In particular, you should evaluate the specific factors under “Risk 
 Factors” of this prospectus supplement for risks related to an investment in the notes, in addition to the risk factors included in the 2024 Form 20-F.                                                                                   |

| Trustee, Security Registrar, Paying Agent and Calculation Agent | Deutsche Bank Trust Company Americas. |

| Listing | We do not intend to list the notes on any securities exchange or automated quotation system. |

| Governing Law | New York. |

| Use of Proceeds | The net proceeds of the offering, after deduction of underwriting discounts and commissions and expenses, amount to approximately $2,986,198,000. |

| We intend to use the net proceeds for general corporate purposes. |

S-13

RISK FACTORS We urge you to carefully review the risks described below, together with the risks described in the documents incorporated by reference into this prospectus supplement and the attached prospectus to the extent supplemented or superseded by the risks described below before you decide to purchase the notes. In particular, you should review the risks relating to our business included in our 2024 Form 20-F,incorporated by reference herein, and any similar disclosure in any subsequent report. If any of these risks actually occur, our business, financial condition and results of operations could suffer, and the trading price and liquidity of the notes offered by this prospectus supplement and the attached prospectus could decline, in which case you may lose all or part of your investment. Risks relating to an investment in the notes We may incur substantially more debt in the future. We may incur substantial additional indebtedness in the future, including in connection with future acquisitions, some of which may be secured by our assets. The terms of the notes issuable hereunder and the indenture under which the notes are issued will not limit the amount of indebtedness we may incur. Any such incurrence of additional indebtedness could exacerbate the risks that holders of the notes currently face. At